T cell engagers have transformed treatment in hematologic cancers but continue to face major barriers in solid tumors. Evotec’s BiTco (Bispecific T cell co-stimulator) platform is designed to overcome these limitations by introducing CD2-mediated costimulation, enhancing T cell activation and tumor cell killing. By combining innovative biology with robust analytical workflows and flexible partnering models, BiTco offers a differentiated approach to unlocking the full potential of T cell engager therapies in solid tumor indications.